Innoviva Inc (INVA)vsMerck & Company Inc (MRK)
INVA
Innoviva Inc
$22.99
-0.26%
HEALTHCARE · Cap: $1.71B
MRK
Merck & Company Inc
$109.18
-1.60%
HEALTHCARE · Cap: $274.03B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 15705% more annual revenue ($65.01B vs $411.33M). INVA leads profitability with a 65.9% profit margin vs 28.1%. INVA appears more attractively valued with a PEG of 0.35. INVA earns a higher WallStSmart Score of 84/100 (A-).
INVA
Exceptional Buy84
out of 100
Grade: A-
MRK
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for INVA.
Margin of Safety
-13.2%
Fair Value
$96.48
Current Price
$109.18
$12.70 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Attractively priced relative to earnings
Reasonable price relative to book value
Keeps 66 of every $100 in revenue as profit
Strong operational efficiency at 34.7%
Earnings expanding 590.0% YoY
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 32.8%
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Generating 1.8B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
Weak financial health signals
Expensive relative to growth rate
Earnings declined 19.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : INVA
The strongest argument for INVA centers on PEG Ratio, P/E Ratio, Price/Book. Profitability is solid with margins at 65.9% and operating margin at 34.7%. Revenue growth of 24.8% demonstrates continued momentum.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.
Bear Case : INVA
The primary concerns for INVA are Market Cap.
Bear Case : MRK
The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
INVA profiles as a growth stock while MRK is a value play — different risk/reward profiles.
INVA carries more volatility with a beta of 0.40 — expect wider price swings.
INVA is growing revenue faster at 24.8% — sustainability is the question.
MRK generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
INVA scores higher overall (84/100 vs 59/100), backed by strong 65.9% margins and 24.8% revenue growth. Both earn "Exceptional Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Innoviva Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Innoviva, Inc. is dedicated to the development and commercialization of pharmaceutical products. The company is headquartered in Burlingame, California.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?